Optimizing gene delivery vectors for the treatment of heart disease

Steven J. Gray, R. Jude Samulski

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

Background: Cardiac gene therapy is approaching reality, with clinical trials entering Phase II/III. Even so, challenges exist to improve the efficacy of even the most successful therapies. Objective: The merits of different gene therapy vectors are weighed to assess the current feasibility of each in specific cardiac applications. Major obstacles are discussed, along with recent advances in vector development to overcome or circumvent those difficulties. Methods: This review focuses primarily on gene delivery via naked DNA, adenovirus, lentivirus, and adeno-associated virus (AAV) vectors. Conclusion: Gene therapy via adenovirus and AAV vectors has developed into a promising option for the treatment of heart disease. The merits of gene therapy compared with emerging stem cell and microRNA-based treatments are discussed.

Original languageEnglish (US)
Pages (from-to)911-922
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume8
Issue number7
DOIs
StatePublished - Jul 1 2008

Fingerprint

Gene therapy
Genetic Therapy
Heart Diseases
Genes
Dependovirus
Viruses
Adenoviridae
Lentivirus
Phase II Clinical Trials
Therapeutics
Stem cells
MicroRNAs
Stem Cells
DNA

Keywords

  • AAV
  • Ad
  • Adeno-associated virus
  • Adenovirus
  • Gene therapy
  • Heart
  • Lentivirus
  • Myocardium
  • Plasmid

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

Optimizing gene delivery vectors for the treatment of heart disease. / Gray, Steven J.; Samulski, R. Jude.

In: Expert Opinion on Biological Therapy, Vol. 8, No. 7, 01.07.2008, p. 911-922.

Research output: Contribution to journalReview article

@article{ae66a164c8924366865c8d3198b196b4,
title = "Optimizing gene delivery vectors for the treatment of heart disease",
abstract = "Background: Cardiac gene therapy is approaching reality, with clinical trials entering Phase II/III. Even so, challenges exist to improve the efficacy of even the most successful therapies. Objective: The merits of different gene therapy vectors are weighed to assess the current feasibility of each in specific cardiac applications. Major obstacles are discussed, along with recent advances in vector development to overcome or circumvent those difficulties. Methods: This review focuses primarily on gene delivery via naked DNA, adenovirus, lentivirus, and adeno-associated virus (AAV) vectors. Conclusion: Gene therapy via adenovirus and AAV vectors has developed into a promising option for the treatment of heart disease. The merits of gene therapy compared with emerging stem cell and microRNA-based treatments are discussed.",
keywords = "AAV, Ad, Adeno-associated virus, Adenovirus, Gene therapy, Heart, Lentivirus, Myocardium, Plasmid",
author = "Gray, {Steven J.} and Samulski, {R. Jude}",
year = "2008",
month = "7",
day = "1",
doi = "10.1517/14712598.8.7.911",
language = "English (US)",
volume = "8",
pages = "911--922",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Optimizing gene delivery vectors for the treatment of heart disease

AU - Gray, Steven J.

AU - Samulski, R. Jude

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Background: Cardiac gene therapy is approaching reality, with clinical trials entering Phase II/III. Even so, challenges exist to improve the efficacy of even the most successful therapies. Objective: The merits of different gene therapy vectors are weighed to assess the current feasibility of each in specific cardiac applications. Major obstacles are discussed, along with recent advances in vector development to overcome or circumvent those difficulties. Methods: This review focuses primarily on gene delivery via naked DNA, adenovirus, lentivirus, and adeno-associated virus (AAV) vectors. Conclusion: Gene therapy via adenovirus and AAV vectors has developed into a promising option for the treatment of heart disease. The merits of gene therapy compared with emerging stem cell and microRNA-based treatments are discussed.

AB - Background: Cardiac gene therapy is approaching reality, with clinical trials entering Phase II/III. Even so, challenges exist to improve the efficacy of even the most successful therapies. Objective: The merits of different gene therapy vectors are weighed to assess the current feasibility of each in specific cardiac applications. Major obstacles are discussed, along with recent advances in vector development to overcome or circumvent those difficulties. Methods: This review focuses primarily on gene delivery via naked DNA, adenovirus, lentivirus, and adeno-associated virus (AAV) vectors. Conclusion: Gene therapy via adenovirus and AAV vectors has developed into a promising option for the treatment of heart disease. The merits of gene therapy compared with emerging stem cell and microRNA-based treatments are discussed.

KW - AAV

KW - Ad

KW - Adeno-associated virus

KW - Adenovirus

KW - Gene therapy

KW - Heart

KW - Lentivirus

KW - Myocardium

KW - Plasmid

UR - http://www.scopus.com/inward/record.url?scp=47549106017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47549106017&partnerID=8YFLogxK

U2 - 10.1517/14712598.8.7.911

DO - 10.1517/14712598.8.7.911

M3 - Review article

C2 - 18549322

AN - SCOPUS:47549106017

VL - 8

SP - 911

EP - 922

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -